I-Aripiprazole CAS 129722-12-9 Purity >99.0% (HPLC) API
Abahlinzeki Bempahla Abaphakathi Be-Aripiprazole Ngokuhlanzeka Okuphezulu
I-Aripiprazole API CAS 129722-12-9
1-(2,3-Dichlorophenyl)piperazine Hydrochloride CAS 119532-26-2
I-7-Hydroxy-3,4-Dihydro-2(1H)-Quinolinone CAS 22246-18-0
7-(4-Bromobutoxy)-3,4-Dihydro-2(1H)-Quinolinone CAS 129722-34-5
| Igama Lekhemikhali | I-Aripiprazole |
| Omqondofana | 7-[4-[4-(2,3-Dichlorophenyl)-1-Piperazinyl]butoxy]-3,4-Dihydro-2(1H)-Quinolinone |
| Inombolo ye-CAS | 129722-12-9 |
| Inombolo yeCAT | I-RF-PI2270 |
| Isimo Sesitoko | Esitokweni, Isikali Sokukhiqiza Sifinyelela Kumathani |
| I-Molecular Formula | I-C23H27Cl2N3O2 |
| Isisindo samangqamuzana | 448.39 |
| Ukuncibilika | I-Soluble Engancibiliki Emanzini;Ayincibiliki ku-Methanol |
| Ibhrendi | I-Ruifu Chemical |
| Into | Imininingwane |
| Ukubukeka | I-Crystalline Powder Emhlophe noma Cishe Emhlophe |
| Ukuhlonza | Nge-IR;Nge-HPLC |
| Ukuncibilika | I-Soluble ku-Acetic Acid, Incibilika Kancane ku-Ethanol |
| I-Melting Point | 136.0 ~ 140.0℃ |
| Ukulahlekelwa Ekumisweni | <0.50% |
| Izinsalela ekushiseni | <0.10% |
| Izinsimbi Ezisindayo | ≤20ppm |
| Izincibilikisi Ezisele | |
| I-Ethanol | ≤1000ppm |
| I-DMF | ≤200ppm |
| Izinto Ezihlobene | |
| Noma Ikuphi Ukungcola Okukodwa | <0.20% |
| Ukungcola Okuphelele | <1.00% |
| Ukuhlanzeka / Indlela Yokuhlaziya | >99.0% (HPLC) |
| Isivivinyo | 98.0%~102.0% (ku-Anhydrous Basis) |
| Imikhawulo emincane | |
| Isamba se-Aerobic Microbial Count | ≤1000 cfu/g |
| Imvubelo nesikhunta Kuhlanganisiwe | ≤100 cfu/g |
| E·Coli | Ukungabikho |
| Ukuhlelwa kwePathogenic | Ukungabikho |
| Izinga Lokuhlola | I-Enterprise Standard |
| Ukusetshenziswa | I-API;I-Antipsychotic |
Iphakheji: Ibhodlela, 5kg/Aluminium tin, 25kg/Cardboard Drum, noma ngokuvumelana nemfuneko yekhasimende
Isimo Sesitoreji:Gcina ezitsheni ezivaliwe endaweni epholile neyomile;Vikela ekukhanyeni nakumswakama
I-Aripiprazole (i-CAS: 129722-12-9) iwuhlobo olusha lokuphuma kokuphuma kwe-quinoline okuncibilika kakhulu kwe-lipid, isici sayo semiphumela yezemithi ukuthi akuyona kuphela i-postsynaptic dopamine D2 receptor antagonist, kodwa futhi i-presynaptic dopamine D2 receptor agonist, ingaphinda jabulisa i-D1, D3, D4 receptors.I-Aripiprazole iyisizukulwane sesibili se-atypical antipsychotic kanye ne-anti-depressant enomsebenzi we-agonist oyingxenye ku-dopamine D2 kanye ne-serotonin 5-HT1A receptors kanye nomsebenzi ophikisayo kuma-serotonin 5-HT2A receptors.Amanani e-Ki angu-0.34 nM, 0.8 nM, 1.7 nM, kanye no-3.4 nM, ngokulandelanayo, ku-dopamine D2 ne-D3, i-serotonin 5-HT1A kanye ne-5-HT2A receptors.I-Aripiprazole isetshenziselwa ukwelapha i-schizophrenia kanye nokuphazamiseka kwengqondo okuhlobene.I-Bristol-Myers Squibb kanye ne-Otsuka Pharmaceutical Company bamemezele ukuthi i-European Union igunyaze i-Abilify (Aripiprazole) ekwelapheni isicelo sohlu lwe-schizophrenia.I-schizophrenia ithinta u-1% wabantu bomhlaba, futhi ngaphezulu kwabancane abadala.I-schizophrenia ithinta ukucabanga, ukulawula imizwa kanye nekhono lokuthatha izinqumo lesiguli.Iziguli ezine-schizophrenia-positive zizoba nezimpawu ezinjengokubona izinto ezingekho kanye nokukhohlisa, iziguli ezinezimpawu ezingezinhle ukuhoxa emphakathini, ukuntuleka kwezinguquko ezingokomzwelo.Ngo-2002 i-FDA igunyaze i-Abilify yokwelapha i-schizophrenia, enamandla omthamo amahlanu: 5 mg, 10 mg, 15 mg, 20 mg kanye nama-30 mg, kusukela ekugunyazweni kwayo.
